TY - JOUR
T1 - Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-Tnf
T2 - Neutrophil-To-lymphocyte ratio and platelet-To-lymphocyte ratio
AU - Bertani, Lorenzo
AU - Rossari, Federico
AU - Barberio, Brigida
AU - Demarzo, Maria Giulia
AU - Tapete, Gherardo
AU - Albano, Eleonora
AU - Svizzero, Giovanni Baiano
AU - Ceccarelli, Linda
AU - Mumolo, Maria Gloria
AU - Brombin, Chiara
AU - Bortoli, Nicola De
AU - Bellini, Massimo
AU - Marchi, Santino
AU - Bodini, Giorgia
AU - Savarino, Edoardo
AU - Costa, Francesco
N1 - Publisher Copyright:
© 2020 Oxford University Press. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/10/1
Y1 - 2020/10/1
N2 - Background: Anti-Tumor necrosis factor drugs (anti-TNFs) are widely used for the treatment of ulcerative colitis (UC). However, many patients experience loss of response during the first year of therapy. An early predictor of clinical remission and mucosal healing is needed. The neutrophil-To-lymphocyte ratio (NLR) and platelet-To-lymphocyte ratio (PLR) are markers of subclinical inflammation poorly evaluated in UC patients treated with anti-TNFs. The aim of this multicenter study was to evaluate whether NLR and PLR could be used as prognostic markers of anti-TNF treatment response. Methods: Patients with UC who started anti-TNF treatment in monotherapy were evaluated. Patients with concomitant corticosteroid treatment 20 mg were excluded. We calculated NLR, PLR, and fecal calprotectin before treatment and after induction. The values of NLR and PLR were correlated with clinical remission and mucosal healing at the end of follow-up (54 weeks) using the Mann-Whitney U test and then multivariate analysis was conducted. Results: Eighty-eight patients were included. Patients who reached mucosal healing after 54 weeks of therapy displayed lower levels of both baseline NLR and PLR (P = 0.0001 and P = 0.04, respectively); similar results were obtained at week 8 (P = 0.0001 and P = 0.001, respectively). Patients who presented with active ulcers at baseline endoscopic evaluation had higher baseline NLR and PLR values compared with those without detected ulcers (P = 0.002 and P = 0.0007, respectively). Conclusions: BothNLR and PLR showed a promising role as early predictors of therapeutic response to anti-TNF therapy in UC patients. If confirmed in larger studies, classification and regression trees proposed in this article could be useful to guide clinical decisions regarding anti-TNF treatment.
AB - Background: Anti-Tumor necrosis factor drugs (anti-TNFs) are widely used for the treatment of ulcerative colitis (UC). However, many patients experience loss of response during the first year of therapy. An early predictor of clinical remission and mucosal healing is needed. The neutrophil-To-lymphocyte ratio (NLR) and platelet-To-lymphocyte ratio (PLR) are markers of subclinical inflammation poorly evaluated in UC patients treated with anti-TNFs. The aim of this multicenter study was to evaluate whether NLR and PLR could be used as prognostic markers of anti-TNF treatment response. Methods: Patients with UC who started anti-TNF treatment in monotherapy were evaluated. Patients with concomitant corticosteroid treatment 20 mg were excluded. We calculated NLR, PLR, and fecal calprotectin before treatment and after induction. The values of NLR and PLR were correlated with clinical remission and mucosal healing at the end of follow-up (54 weeks) using the Mann-Whitney U test and then multivariate analysis was conducted. Results: Eighty-eight patients were included. Patients who reached mucosal healing after 54 weeks of therapy displayed lower levels of both baseline NLR and PLR (P = 0.0001 and P = 0.04, respectively); similar results were obtained at week 8 (P = 0.0001 and P = 0.001, respectively). Patients who presented with active ulcers at baseline endoscopic evaluation had higher baseline NLR and PLR values compared with those without detected ulcers (P = 0.002 and P = 0.0007, respectively). Conclusions: BothNLR and PLR showed a promising role as early predictors of therapeutic response to anti-TNF therapy in UC patients. If confirmed in larger studies, classification and regression trees proposed in this article could be useful to guide clinical decisions regarding anti-TNF treatment.
KW - biomarkers
KW - mucosal healing
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85091325009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091325009&partnerID=8YFLogxK
U2 - 10.1093/ibd/izaa062
DO - 10.1093/ibd/izaa062
M3 - Article
C2 - 32232392
AN - SCOPUS:85091325009
VL - 26
SP - 1579
EP - 1587
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
SN - 1078-0998
IS - 10
ER -